Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients
NCT ID: NCT03016884
Last Updated: 2020-02-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
87 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-01-31
Study Completion Date
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The reactivation of varicella zoster virus (VZV) (herpes zoster (HZ)) is of substantial public health concern. Updated ACR recommendations for RA treatment suggest that RA patients aged ≥ 50 years should be vaccinated before receiving biologic or tofacitinib therapy. The Investigators therefore propose a prospective study to evaluate the safety, tolerability, and immunogenicity of a zoster vaccine (Zostavax) in patients with RA, administered at least 2 weeks prior to initiation of anti-TNF biologic and tofacitinib therapy for RA.
This is a 6-week open-label prospective multi-center study evaluating the safety, tolerability, and immunogenicity of Zostavax vaccine in the RA population prior to initiation of biologic/tofacitinib therapy for RA. VZV-specific immune response to vaccine in RA patients will be compared to healthy control subjects ≥ 50 years immunized with Zostavax.
This is a 6-week open-label prospective multi-center study evaluating the safety, tolerability, and immunogenicity of Zostavax vaccine in the RA population prior to initiation of biologic/tofacitinib therapy for RA. VZV-specific immune response to vaccine in RA patients will be compared to healthy control subjects ≥ 50 years immunized with Zostavax.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of Zostavax Vaccination in Rheumatoid Arthritis
NCT01506661
Rheumatoid Arthritis
Varicella Zoster
COMPLETED
PHASE1
A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate
NCT02147587
Rheumatoid Arthritis
COMPLETED
PHASE2
Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)
NCT03886038
Rheumatoid Arthritis
Healthy Controls
COMPLETED
PHASE4
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
NCT03604406
Herpes Zoster
Inflammatory Disease
Rheumatoid Arthritis
ACTIVE_NOT_RECRUITING
PHASE2
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
NCT07280741
Autoimmune Rheumatic Diseases
NOT_YET_RECRUITING
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Safety and Tolerability of Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Immunized prior to biologics and tofacitinib therapy initiation Background The reactivation of varicella zoster virus (VZV) (herpes zoster (HZ)) is of substantial public health concern. Its predilection for the elderly and immunosuppressed make it an important cause of morbidity, causing pain, depression, and long-term disability in the form of post-herpetic neuralgia. The risk of HZ is increased by 1.5 to 2 times in patients with rheumatoid arthritis (RA) compared with the general population.This increase has been attributed to both the underlying disease process and treatments for RA, in particular, corticosteroids, TNFα blocking agents, rituximab, and tofacitinib.
A live attenuated zoster vaccine, administered as a single subcutaneous injection, reduces HZ risk by 70% and 51% among immunocompetent individuals 50 to 59 years and 60 years and older in 2 randomized blinded trials, respectively.
Updated ACR recommendations for RA treatment suggest that RA patients aged ≥ 50 years should be vaccinated before receiving biologic or tofacitinib therapy. Yet, the real world data proves that only minority of RA patients initiating biologic therapy are vaccinated for herpes zoster.
The safety concern is that these individuals may develop varicella infection from the vaccine virus strain. Recently, zoster vaccine safety, tolerability, and immunogenicity were prospectively tested in patients on chronic low-medium dose of corticosteroid therapy. Zoster vaccine was generally well tolerated and immunogenic in this patient population.
Based on the VZV incubation period, the first 42 days following vaccination was chosen as the primary safety risk window in the Shingles Prevention Study, a randomized blinded trial that preceded the FDA approval of the vaccine.
The investigators therefore propose a prospective study to evaluate the safety, tolerability, and immunogenicity of a zoster vaccine (Zostavax) in patients with RA, administered at least 2 weeks prior to initiation of anti-TNF biologic and tofacitinib therapy for RA. The study will specifically focus on the zoster vaccine related adverse events, including injection site reactions, the development of zoster-like lesions, and the rates of clinical herpes zoster.
Study Objective:
1. To evaluate the rate of adverse reactions, injection site reactions, and development of zoster-like lesions following Zostavax administration.
2. To evaluate the rate of clinical herpes zoster events after initiation of biologic and small molecule therapies for RA following Zostavax administration.
3. To evaluate the immunogenicity of Zostavax in RA patients immunized 2 weeks prior to biologic or tofacitinib therapy.
Study Design:
This is a 6-week open-label prospective multi-center study evaluating the safety, tolerability, and immunogenicity of Zostavax vaccine in the RA population prior to initiation of biologic/tofacitinib therapy for RA. VZV-specific immune response to vaccine in RA patients will be compared to healthy control subjects ≥ 50 years immunized with Zostavax.
Healthy volunteers will be recruited from hospital staff and from relatives of patients who agreed to participate in this studyNine Rheumatology Departments across Israel only will participate in the study. These centers are Tel Aviv Medical Center, Sheba Medical Center, Assaf Harofe Medical Center, Shaare Zedek Medical Center, Rabin Medical Center, Bnei Tsion Medical Center, Rambam MedicaL Center, Hahemek Medical center, Carmel Medical Center.
Vaccine Information:
ZOSTAVAX is a lyophilized preparation of live, attenuated varicella-zoster virus (Oka/Merck strain) to be reconstituted with sterile diluent to give a single dose suspension with a minimum of 19,400 PFU (plaque forming units) when stored at room temperature for up to 30 minutes. It is administered as a single subcutaneous injection into the deltoid region of the upper arm.
Study Visits:
Screening Visit/Vaccination The study Investigator will discuss, with each subject, the nature of the study, its requirements, and its restrictions. Written informed consent must be obtained prior performance of any protocol specific procedures. Upon recruitment, patients will be examined by a treating rheumatologist, in order to verify the diagnosis of RA and review the pertinent to vaccination medical history. Patients will be subsequently assessed for RA disease activity.
Procedures to be performed during the screening period include:
Informed Consent Confirmation of RA diagnosis and Classification of RA: subject must have a score of 6 or greater on the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis Medical History as pertinent to HZ vaccination including history of prior and concomitant medications, history of any prior episodes of herpes zoster, and zoster vaccine history.
Assessment of RA activity:
Blood test (ESR, CRP), varicella-zoster virus (VZV) antibody titers by glycoprotein enzyme-linked immunosorbent assay (gpELISA), (will be carried out centrally at tel Aviv Sourasky medical center Immunology laboratory) and future analysis (excluding any genetic tests).
After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
2- week phone interview based follow up/ Biologic or tofacitinib treatment initiation (etanercept and tofacitinib will comprise 80% of total therapies) At the 2-week visit, vaccine safety will be assessed. Following a two-week interval from the zoster vaccine administration, biologic or tofacitinib treatment will be initiated as scheduled by a treating rheumatologist.
Importantly, no biologic treatment of any kind would be provided by the study project.
4- week phone interview follow up Vaccine safety and adverse effects assessment. 6- week visit Vaccine safety and adverse effects assessment. Assessment of RA activity. Subject Withdrawal Subjects may withdraw from the study at any time at their own request.
Assessments:
Assessment of RA Disease Activity At each study visit, patients will be subsequently assessed for RA disease activity Patient Assessment of Arthritis Pain Patient Global Assessment of Arthritis. Physician Global Assessment of Arthritis Health Assessment Questionnaire - Disability Index (HAQ-DI) Safety Assessment Any adverse reactions/events following zoster vaccine administration will be registered and assessed.
Injection site adverse reactions:
Local pain/erythema/swelling/pruritus/warmth/hematoma/induration Hypersensitivity Post vaccination non-injection-site zoster-like and varicella-like rashes Post vaccination herpes zoster occurrence Systemic adverse reactions Progression/worsening of underlying disease
Adverse effects will be defined according to the following definitions:
MILD Does not interfere with subject's usual function. MODERATE Interferes to some extent with subject's usual function. SEVERE Interferes significantly with subject's usual function.
Blood tests Samples of 15 cc blood only will be taken at two visits: pre-vaccination and post-vaccination (6 weeks). VZV antibody titers will be measured by commercially available ELISA kits.
All data will be deidentified. Only the principal investigator will have access to the table key linking the data sets with personally identifiable information. The study documents will be kept locked at department of rheumatology. The study will be financed by the research funds of the principal investigator.
A live attenuated zoster vaccine, administered as a single subcutaneous injection, reduces HZ risk by 70% and 51% among immunocompetent individuals 50 to 59 years and 60 years and older in 2 randomized blinded trials, respectively.
Updated ACR recommendations for RA treatment suggest that RA patients aged ≥ 50 years should be vaccinated before receiving biologic or tofacitinib therapy. Yet, the real world data proves that only minority of RA patients initiating biologic therapy are vaccinated for herpes zoster.
The safety concern is that these individuals may develop varicella infection from the vaccine virus strain. Recently, zoster vaccine safety, tolerability, and immunogenicity were prospectively tested in patients on chronic low-medium dose of corticosteroid therapy. Zoster vaccine was generally well tolerated and immunogenic in this patient population.
Based on the VZV incubation period, the first 42 days following vaccination was chosen as the primary safety risk window in the Shingles Prevention Study, a randomized blinded trial that preceded the FDA approval of the vaccine.
The investigators therefore propose a prospective study to evaluate the safety, tolerability, and immunogenicity of a zoster vaccine (Zostavax) in patients with RA, administered at least 2 weeks prior to initiation of anti-TNF biologic and tofacitinib therapy for RA. The study will specifically focus on the zoster vaccine related adverse events, including injection site reactions, the development of zoster-like lesions, and the rates of clinical herpes zoster.
Study Objective:
1. To evaluate the rate of adverse reactions, injection site reactions, and development of zoster-like lesions following Zostavax administration.
2. To evaluate the rate of clinical herpes zoster events after initiation of biologic and small molecule therapies for RA following Zostavax administration.
3. To evaluate the immunogenicity of Zostavax in RA patients immunized 2 weeks prior to biologic or tofacitinib therapy.
Study Design:
This is a 6-week open-label prospective multi-center study evaluating the safety, tolerability, and immunogenicity of Zostavax vaccine in the RA population prior to initiation of biologic/tofacitinib therapy for RA. VZV-specific immune response to vaccine in RA patients will be compared to healthy control subjects ≥ 50 years immunized with Zostavax.
Healthy volunteers will be recruited from hospital staff and from relatives of patients who agreed to participate in this studyNine Rheumatology Departments across Israel only will participate in the study. These centers are Tel Aviv Medical Center, Sheba Medical Center, Assaf Harofe Medical Center, Shaare Zedek Medical Center, Rabin Medical Center, Bnei Tsion Medical Center, Rambam MedicaL Center, Hahemek Medical center, Carmel Medical Center.
Vaccine Information:
ZOSTAVAX is a lyophilized preparation of live, attenuated varicella-zoster virus (Oka/Merck strain) to be reconstituted with sterile diluent to give a single dose suspension with a minimum of 19,400 PFU (plaque forming units) when stored at room temperature for up to 30 minutes. It is administered as a single subcutaneous injection into the deltoid region of the upper arm.
Study Visits:
Screening Visit/Vaccination The study Investigator will discuss, with each subject, the nature of the study, its requirements, and its restrictions. Written informed consent must be obtained prior performance of any protocol specific procedures. Upon recruitment, patients will be examined by a treating rheumatologist, in order to verify the diagnosis of RA and review the pertinent to vaccination medical history. Patients will be subsequently assessed for RA disease activity.
Procedures to be performed during the screening period include:
Informed Consent Confirmation of RA diagnosis and Classification of RA: subject must have a score of 6 or greater on the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis Medical History as pertinent to HZ vaccination including history of prior and concomitant medications, history of any prior episodes of herpes zoster, and zoster vaccine history.
Assessment of RA activity:
Blood test (ESR, CRP), varicella-zoster virus (VZV) antibody titers by glycoprotein enzyme-linked immunosorbent assay (gpELISA), (will be carried out centrally at tel Aviv Sourasky medical center Immunology laboratory) and future analysis (excluding any genetic tests).
After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
2- week phone interview based follow up/ Biologic or tofacitinib treatment initiation (etanercept and tofacitinib will comprise 80% of total therapies) At the 2-week visit, vaccine safety will be assessed. Following a two-week interval from the zoster vaccine administration, biologic or tofacitinib treatment will be initiated as scheduled by a treating rheumatologist.
Importantly, no biologic treatment of any kind would be provided by the study project.
4- week phone interview follow up Vaccine safety and adverse effects assessment. 6- week visit Vaccine safety and adverse effects assessment. Assessment of RA activity. Subject Withdrawal Subjects may withdraw from the study at any time at their own request.
Assessments:
Assessment of RA Disease Activity At each study visit, patients will be subsequently assessed for RA disease activity Patient Assessment of Arthritis Pain Patient Global Assessment of Arthritis. Physician Global Assessment of Arthritis Health Assessment Questionnaire - Disability Index (HAQ-DI) Safety Assessment Any adverse reactions/events following zoster vaccine administration will be registered and assessed.
Injection site adverse reactions:
Local pain/erythema/swelling/pruritus/warmth/hematoma/induration Hypersensitivity Post vaccination non-injection-site zoster-like and varicella-like rashes Post vaccination herpes zoster occurrence Systemic adverse reactions Progression/worsening of underlying disease
Adverse effects will be defined according to the following definitions:
MILD Does not interfere with subject's usual function. MODERATE Interferes to some extent with subject's usual function. SEVERE Interferes significantly with subject's usual function.
Blood tests Samples of 15 cc blood only will be taken at two visits: pre-vaccination and post-vaccination (6 weeks). VZV antibody titers will be measured by commercially available ELISA kits.
All data will be deidentified. Only the principal investigator will have access to the table key linking the data sets with personally identifiable information. The study documents will be kept locked at department of rheumatology. The study will be financed by the research funds of the principal investigator.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Herpes Zoster
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RA patients
RA patients will be administered Zostavax vaccine once 2 weeks before initiation of bDMARD, and be monitored accordingly
Group Type
EXPERIMENTAL
Zostavax vaccine
Intervention Type
BIOLOGICAL
After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
Healthy Controls
healthy control patients will be administered Zostavax vaccine and be monitored accordingly
Group Type
EXPERIMENTAL
Zostavax vaccine
Intervention Type
BIOLOGICAL
After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zostavax vaccine
After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
ZOSTAVAX® (Zoster Vaccine Live)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
2. Patients fulfilling the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for RA scheduled for a biologic or small molecule therapy (80% candidates for etanercept or tofacitinib therapies.)
3. Only subjects who are ≥ 50 years old will be administered the zoster vaccine.
4. Subjects who are willing and able to comply with scheduled visits and other study procedures
5. Patients on biologics may participate after a washout period as indicated below :
1. Etanercept : 2 weeks
2. Infliximab, Golimumab, Adalimumab : 35 days
3. Tocilizumab and Abatacept SC : 2 weeks
4. Tocilizumab and Abatacept IV : 35 days
2. Patients fulfilling the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for RA scheduled for a biologic or small molecule therapy (80% candidates for etanercept or tofacitinib therapies.)
3. Only subjects who are ≥ 50 years old will be administered the zoster vaccine.
4. Subjects who are willing and able to comply with scheduled visits and other study procedures
5. Patients on biologics may participate after a washout period as indicated below :
1. Etanercept : 2 weeks
2. Infliximab, Golimumab, Adalimumab : 35 days
3. Tocilizumab and Abatacept SC : 2 weeks
4. Tocilizumab and Abatacept IV : 35 days
Exclusion Criteria
1. History of anaphylactic/anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine.
2. Previous vaccination with any VZV-containing vaccine.
3. Any type of malignancy, ongoing chemotherapy or radiation therapy.
4. Patients who underwent solid organ transplantation.
5. Patients with AIDS or clinical manifestations of HIV
6. Patients treated with a TNFa inhibitor at the time of recruitment or patients within a year of rituximab administration.
7. Patients receiving daily corticosteroid therapy with a dose ≥10 mg/day of prednisone (or equivalent) for ≥ 14 days and/or methotrexate at the dose above 0.4 mg per kg per week.
8. Patients with an active herpes zoster infection or previous herpes zoster less than 6 months before recruitment.
9. Vaccination with any live vaccine within 4 weeks prevaccination, any inactivated vaccine within 7 days prevaccination, or either during the study period.
10. Blood products transfusion within 5 months prior to vaccination through the study period.
11. Patients with active tuberculosis.
12. History of Guillain-Barre Syndrome
for healthy arm: Inclusion subjects who are ≥ 50 years old will be administered the zoster vaccine.
Exclusion
1. History of past or present autoimmune diseases
2. History or current use of immunosuppressive drugs
3. History of anaphylactic/anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine.
4. .Previous vaccination with any VZV-containing vaccine.
5. Any type of malignancy, ongoing chemotherapy or radiation therapy.
6. History of underwent solid organ transplantation.
7. Active herpes zoster infection or previous herpes zoster less than 6 months before recruitment.
8. Vaccination with any live vaccine within 4 weeks prevaccination, any inactivated vaccine within 7 days prevaccination, or either during the study period.
9. Blood products transfusion within 5 months prior to vaccination through the study period.
2. Previous vaccination with any VZV-containing vaccine.
3. Any type of malignancy, ongoing chemotherapy or radiation therapy.
4. Patients who underwent solid organ transplantation.
5. Patients with AIDS or clinical manifestations of HIV
6. Patients treated with a TNFa inhibitor at the time of recruitment or patients within a year of rituximab administration.
7. Patients receiving daily corticosteroid therapy with a dose ≥10 mg/day of prednisone (or equivalent) for ≥ 14 days and/or methotrexate at the dose above 0.4 mg per kg per week.
8. Patients with an active herpes zoster infection or previous herpes zoster less than 6 months before recruitment.
9. Vaccination with any live vaccine within 4 weeks prevaccination, any inactivated vaccine within 7 days prevaccination, or either during the study period.
10. Blood products transfusion within 5 months prior to vaccination through the study period.
11. Patients with active tuberculosis.
12. History of Guillain-Barre Syndrome
for healthy arm: Inclusion subjects who are ≥ 50 years old will be administered the zoster vaccine.
Exclusion
1. History of past or present autoimmune diseases
2. History or current use of immunosuppressive drugs
3. History of anaphylactic/anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine.
4. .Previous vaccination with any VZV-containing vaccine.
5. Any type of malignancy, ongoing chemotherapy or radiation therapy.
6. History of underwent solid organ transplantation.
7. Active herpes zoster infection or previous herpes zoster less than 6 months before recruitment.
8. Vaccination with any live vaccine within 4 weeks prevaccination, any inactivated vaccine within 7 days prevaccination, or either during the study period.
9. Blood products transfusion within 5 months prior to vaccination through the study period.
Minimum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ha'Emek Medical center, Unit of Rheumatology
Afula, , Israel
Site Status
Carmel Medical Center
Haifa, , Israel
Site Status
Tel Aviv Medical Center, Unit pf Rheumatology
Tel Aviv, , Israel
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Israel
References
Explore related publications, articles, or registry entries linked to this study.
Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007 Dec 15;57(8):1431-8. doi: 10.1002/art.23112.
Reference Type
BACKGROUND
Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, Yazdany J. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA. 2011 Feb 2;305(5):480-6. doi: 10.1001/jama.2011.67.
Reference Type
BACKGROUND
Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Mar;65(3):353-61. doi: 10.1002/acr.21812.
Reference Type
BACKGROUND
Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, Saag KG, Singh J, Curtis JR. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol. 2016 Sep;68(9):2328-37. doi: 10.1002/art.39670.
Reference Type
BACKGROUND
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.
Reference Type
BACKGROUND
Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct;75(10):1843-7. doi: 10.1136/annrheumdis-2016-209131. Epub 2016 Apr 25.
Reference Type
BACKGROUND
Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr;54(7):922-8. doi: 10.1093/cid/cir970. Epub 2012 Jan 30.
Reference Type
BACKGROUND
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271-84. doi: 10.1056/NEJMoa051016.
Reference Type
BACKGROUND
Calabrese LH, Calabrese C, Kirchner E. The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al. Arthritis Care Res (Hoboken). 2016 May;68(5):723-4. doi: 10.1002/acr.22865. No abstract available.
Reference Type
BACKGROUND
Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015 May;67(5):731-6. doi: 10.1002/acr.22470.
Reference Type
BACKGROUND
Koshima I, Higaki H, Soeda S. Combined vascularized fibula and peroneal composite-flap transfer for severe heat-press injury of the forearm. Plast Reconstr Surg. 1991 Aug;88(2):338-41. doi: 10.1097/00006534-199108000-00030.
Reference Type
BACKGROUND
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. No abstract available.
Reference Type
BACKGROUND
Russell AF, Parrino J, Fisher CL Jr, Spieler W, Stek JE, Coll KE, Su SC, Xu J, Li X, Schlienger K, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015 Jun 17;33(27):3129-34. doi: 10.1016/j.vaccine.2015.04.090. Epub 2015 May 8.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
142-016-EMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
NCT05879419
ACTIVE_NOT_RECRUITING
PHASE4
Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT
NCT04748939
NOT_YET_RECRUITING
PHASE4
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
NCT06763783
ENROLLING_BY_INVITATION
PHASE4
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
NCT05236491
UNKNOWN
PHASE2/PHASE3
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
NCT01988012
COMPLETED
PHASE3
Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases
NCT07341386
NOT_YET_RECRUITING
PHASE4
Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine
NCT01980836
UNKNOWN
PHASE4
Effect of MTX Discontinuation on Shingrix Response in RA
NCT06574594
RECRUITING
NA
The Effect of Rituximab on the Humoral Response to Influenza Vaccine
NCT00466037
TERMINATED
NA
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
NCT00531817
COMPLETED
PHASE3
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
NCT00996203
COMPLETED
PHASE4
Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis
NCT01002716
UNKNOWN
PHASE4
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
NCT01163747
COMPLETED
PHASE4
A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis
NCT00965653
COMPLETED
PHASE1
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
NCT01382940
COMPLETED
PHASE4
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.
NCT00036387
COMPLETED
PHASE3
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
NCT00443651
COMPLETED
PHASE3
A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis
NCT00236028
COMPLETED
PHASE3
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT01232569
COMPLETED
PHASE3
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
NCT02001987
COMPLETED
PHASE3
A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting
NCT05487703
COMPLETED
A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
NCT02281552
COMPLETED
PHASE3
Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
NCT01932372
COMPLETED